Dupixent (dupilumab) is currently the most successful biologic treatment for moderate-to-severe atopic dermatitis,...
- How Dupixent is establishing itself as the premier dermatology treatment
- Epilepsy drug sales to hit $7.5bn by 2026
- Billion-dollar deals mean bright future for Takeda
- European Commission approves AstraZeneca’s Fasenra for asthma
- M&As this week: CSPC NBP Pharmaceutical, International Finance Corporation, Sun Pharmaceutical
MediSapiens Joins Pistoia Alliance to Collaborate with Life Science Peers on New Innovations
MediSapiens has collaborated with The Pistoia Alliance, a global, non-profit alliance of life science companies, vendors, publishers and academic groups.
How Dupixent is establishing itself as the premier dermatology treatment
Dupixent (dupilumab) is currently the most successful biologic treatment for moderate-to-severe atopic dermatitis, developed by a joint venture between Regeneron Pharmaceuticals and Sanofi Genzyme.
Worker Preferences and Workplace Agility
Worker Preferences and Workplace Agility canvasses the value employees attach to key elements of their work, including skills, flexible work arrangements, and even the idea of socially conscious work.
Billion-dollar deals mean bright future for Takeda
Takeda has taken a massive step forward in its partnership and acquisition deals over the past year, totaling over a billion dollars. Their CEO, Christophe Weber, stated that the company’s goal is to become more versatile and diverse, hence its deals with biotechnology firms, while still holding the financial punch of a Big Pharma company.
European Commission approves AstraZeneca’s Fasenra for asthma
AstraZeneca and its global biologics research and development arm MedImmune have received approval from the European Commission (EC) for their Fasenra (benralizumab) for the treatment of severe eosinophilic asthma in adult patients.
M&As this week: CSPC NBP Pharmaceutical, International Finance Corporation, Sun Pharmaceutical
CSPC NBP Pharmaceutical, a subsidiary of CSPC Pharmaceutical Group, has signed an equity transfer and capital increase agreement with Wuhan YZY Biopharma’s investors, vendors and shareholders to acquire 39.56% in the company for CNY356m ($54.78m).
Deals this week: Melinta Therapeutics, Cipher Pharmaceuticals, Baxter International
Melinta Therapeutics plans to raise $114.88m by issuing 6,920,714 shares of its common stock, priced at $16.6 a share.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.